Basu A
Department of Pharmacology, University of Pittsburgh School of Medicine, PA 15261.
Pharmacol Ther. 1993 Sep;59(3):257-80. doi: 10.1016/0163-7258(93)90070-t.
Many investigators have embarked upon the search for novel cellular targets for the treatment of cancer. A popular therapeutic strategy is to intervene with the components of cellular signalling systems that are altered during malignancy. The molecular heterogeneity of the protein kinase C (PKC) family and their functional divergence make them attractive targets for anticancer drug development. PKC can also influence the sensitivity of tumor tissue to conventional cytotoxic drugs. As discussed in this review, a complete understanding of the PKC signal transduction pathway is obligatory for the selective destruction of tumor tissue by exploiting PKC as either a target or a modulator of cancer chemotherapeutic agents.
许多研究人员已着手寻找用于治疗癌症的新型细胞靶点。一种常用的治疗策略是干预在恶性肿瘤发生过程中发生改变的细胞信号系统的组成部分。蛋白激酶C（PKC）家族的分子异质性及其功能差异使其成为抗癌药物开发的有吸引力的靶点。PKC还可影响肿瘤组织对传统细胞毒性药物的敏感性。如本综述中所讨论的，通过将PKC用作癌症化疗药物的靶点或调节剂来选择性破坏肿瘤组织，对PKC信号转导途径的全面了解必不可少。
